Cargando…

Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma

Background: Lenvatinib is in a first-line therapy for advanced hepatocellular carcinoma (HCC). However, drug resistance is one of the principal obstacles for treatment failure. The molecular mechanism of Lenvatinib resistance has not been well investigated. Materials and methods: A genome-wide CRISP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shanzhou, Ma, Zuyi, Zhou, Qi, Wang, Aimei, Gong, Yuanfeng, Li, Zhenchong, Wang, Shujie, Yan, Qian, Wang, Dongping, Hou, Baohua, Zhang, Chuanzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295068/ https://www.ncbi.nlm.nih.gov/pubmed/35864956 http://dx.doi.org/10.7150/ijbs.69969

Ejemplares similares

Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy
por: Zhuang, Hongkai, et al.
Publicado: (2021)

CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer
por: Zhou, Zixuan, et al.
Publicado: (2021)

ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway
por: Ma, Zuyi, et al.
Publicado: (2022)

Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas
por: Zhuang, Hongkai, et al.
Publicado: (2021)

SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma
por: Ma, Zuyi, et al.
Publicado: (2021)

Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8(+) T-Cell Infiltration in Pancreatic Cancer
por: Li, Zhenchong, et al.
Publicado: (2022)

A hierarchical prognostic model for Co-diabetes pancreatic adenocarcinoma
por: Wu, Zelong, et al.
Publicado: (2023)

Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of pancreatic cancer
por: Li, Zhenchong, et al.
Publicado: (2022)

Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma
por: Ma, Zuyi, et al.
Publicado: (2021)

A Novel Prognostic Nomogram for Gallbladder Cancer after Surgical Resection: A Single-Center Experience
por: Ma, Zuyi, et al.
Publicado: (2021)

B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8(+) T cells in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer
por: Ma, Zuyi, et al.
Publicado: (2021)

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
por: Lu, Yonggang, et al.
Publicado: (2021)

A four prognosis-associated lncRNAs (PALnc) based risk score system reflects immune cell infiltration and predicts patient survival in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Correction: Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
por: Lu, Yonggang, et al.
Publicado: (2022)

CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma
por: Zheng, Adi, et al.
Publicado: (2019)

Minimal genome-wide human CRISPR-Cas9 library
por: Gonçalves, Emanuel, et al.
Publicado: (2021)

CRISPR/Cas-based customization of pooled CRISPR libraries
por: Kweon, Jiyeon, et al.
Publicado: (2018)

DUSP2 deletion with CRISPR/Cas9 promotes Mauthner cell axonal regeneration at the early stage of zebrafish
por: Shao, Guo-Jian, et al.
Publicado: (2022)

Prognostic values and immune suppression of the S100A family in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2021)

Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library
por: Wu, Yuanzhong, et al.
Publicado: (2020)

Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma
por: Huang, Shanzhou, et al.
Publicado: (2020)

Incidental intraoperative finding of gallbladder duplication in a patient with a choledochal cyst
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis
por: Zhang, Jingjing, et al.
Publicado: (2022)

Cas-Database: web-based genome-wide guide RNA library design for gene knockout screens using CRISPR-Cas9
por: Park, Jeongbin, et al.
Publicado: (2016)

A CRISPR-Cas9 library screening identifies CARM1 as a critical inhibitor of ferroptosis in hepatocellular carcinoma cells
por: Cheng, Yiming, et al.
Publicado: (2023)

Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach
por: Chari, Raj, et al.
Publicado: (2015)

Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities
por: Sanson, Kendall R., et al.
Publicado: (2018)

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
por: Wei, Lai, et al.
Publicado: (2019)

DUSP12 regulates the tumorigenesis and prognosis of hepatocellular carcinoma
por: Ju, Gaoda, et al.
Publicado: (2021)

DUSP5 and DUSP6 modulate corneal epithelial cell proliferation
por: Wang, Zheng, et al.
Publicado: (2010)

CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives
por: Chan, Yau-Tuen, et al.
Publicado: (2022)

Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Responsive Cells for rhEGF bioassay Obtained through Screening of a CRISPR/Cas9 Library
por: Qin, Xi, et al.
Publicado: (2019)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gdnivl4m3qmfhivfgo6ko7vejq